Rami Elghandour, Arcellx CEO
Updated: Gilead, Arcellx team up on anti-BCMA CAR-T as biotech touts a 100% response rate at #ASH22
Gilead and Kite are plunking down big cash to get into the anti-BCMA CAR-T game.
The pair will shell out $225 million in cash upfront …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
